Metropolis Healthcare Limited — PPTs, 04-08-2026: Investor Presentation

Metropolis Healthcare delivered strong Q1FY27 results: Revenue rose 17% YoY to ₹450 Cr, PAT jumped 26% YoY to ₹57 Cr, and EBITDA increased 27% YoY to ₹113 Cr, boosting margins. Growth was primarily volume-driven, with patient volumes up 10% (3.7 Mn) and test volumes climbing 11% (7.8 Mn).

B2C revenue surged 18% to ₹257 Cr, fueled by micro-marketing and Tier-3 expansion. TruHealth and Specialty segments were standout performers, growing 22% and 17% respectively. The company expanded its network to 209 labs and 5,003 service points.

The "Metropolis 3.0" strategy focuses on leveraging AI and digital innovation to enhance customer experience and drive consistent, profitable growth. Recent developments include new tech platforms, AI-enabled wellness programs, and 36 new tests launched this quarter. Management highlighted outperforming growth guidance, indicating robust underlying demand supported by efficiency gains.